statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

HC Wainwright reissued their buy rating on shares of Lumos Pharma (NASDAQ:LUMO  Free Report) in a report published on Wednesday morning, Benzinga reports. They currently have a $28.00 target...

Lumos Pharma (NASDAQ:LUMO) Earns Buy Rating from HC Wainwright

AUSTIN, Texas, March 20, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency...

Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042

Theres a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Poseida Therapeutics (PSTX Research Report), Lumos Pharma...

Analysts Are Bullish on Top Healthcare Stocks: Poseida Therapeutics (PSTX), Lumos Pharma (LUMO)

End of Phase 2 Meeting to Occur in Q2 2024, Initiation of LUM-201 Phase 3 Trial Expected in Q4 2024 Previously Announced Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201...

Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update

AUSTIN, Texas, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD...

Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024

AUSTIN, Texas, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone...

Lumos Pharma to Participate in Oppenheimer's 34th Annual Healthcare Life Sciences Conference

AUSTIN, Texas, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, has promoted Pisit Duke...

Lumos Pharma Promotes Pisit  Duke  Pitukcheewanont, MD to Chief Medical Officer

Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for rare diseases. Its product includes LUM-201, an oral growth hormone stimulating small molecule for the treatment of pediatric growth hormone deficiency (PGHD). The company was founded on June 4, 1999 and is headquartered in Austin, TX.

Volume	69,636.00
52-Wk High	$4.55
52-Wk Low	$2.41

Period	Estimated	Reported	Surprise	Result
Q1'24	-$1.14	--	--	N/A
Q4'23	-$1.14	-$1.16	-1.93%	MISSED
Q3'23	-$1.15	-$1.04	9.41%	BEAT
Q2'23	-$1.10	-$1.09	0.61%	BEAT
Q1'23	-$1.12	-$0.89	20.18%	BEAT

LUMO Lumos Pharma Inc

About

Feed

News

Sentiment

Earnings

Fundamentals